Please try another search
Recce Pharmaceuticals Ltd, a biotechnology company, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United States, and the United Kingdom. The company’s lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use. In addition, the company engages in R327 Intravenous which provides serious/life-threatening bacterial infections, including sepsis which is in the phase 1 trial; urinary tract infections, including urosepsis; rapid infusions sepsis in the phase 2 trial; and R327 Topical offers wound infections, including infected burns; and diabetic foot ulcer infections in Phase 2 trails. Further, the company operates various pre-clinical programs, such as Mycobacterium abscessus which is in phase 1 clinical trial; bacterial sinusitis; and additional TBA. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
Name | Age | Since | Title |
---|---|---|---|
Michele Keryn Diliza | - | 2015 | Chief Scientific Director & Executive Director |
James Hamilton-Bray Graham | - | 2015 | CEO, MD & Executive Director |
John K. A. Prendergast | 69 | 2018 | Executive Chairman of the Board |
Alistair McKeough | - | 2017 | Non-Executive Director |
Justin Ward | - | 2019 | Principal Quality Chemist & Executive Director |
Alan W. Dunton | 69 | 2020 | Chief Medical Advisor & Independent Non Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review